MediSave.ca is Moving!

Dostinex Information:

DOSTINEX(Cabergoline) Tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. Cabergoline is a long-acting dopamine receptor agonist with a high affinity for D2 Dopamine receptors. Dopamine agonists such as DOSTINEX(Cabergoline) in general should not be used in patients with pregnancy-induced hypertension, for example, preeclampsia and eclampsia, unless the potential benefit is judged to outweigh the possible risk. The prolactin-lowering action of cabergoline suggests that it will interfere with lactation. Due to this interference with lactation, DOSTINEX(Cabergoline) should not be given to women postpartum who are breastfeeding or who are planning to breastfeed. DOSTINEX (Cabergoline) Tablets are white, scored, capsule-shaped tablets containing 0.5 mg cabergoline. Each tablet of DOSTINEX (Cabergoline) is scored on one side and has the letter P and the letter U on either side of the breakline. The other side of the DOSTINEX(Cabergoline) tablet is engraved with the number 700. DOSTINEX (Cabergoline) is avilable in bottles of 8 tablets.

Dostinex Side Effects:

DOSTINEX(Cabergoline) side effects include: nausea, constipation, abdominal pain, dyspepsia and vomiting, headache, and dizziness. Initial doses higher than DOSTINEX(Cabergoline) 1.0 mg may produce DOSTINEX(Cabergoline) side effects like orthostatic hypotension. Care should be exercised when administering DOSTINEX(Cabergoline) with other medications known to produce DOSTINEX(Cabergoline) side effects like lower blood pressure.

The recommended dosage of DOSTINEX(Cabergoline) Tablets for initiation of therapy is 0.25 mg twice a week. Dosage may be increased by 0.25 mg twice weekly up to a dosage of 1 mg twice a week according to the patient's serum prolactin level. Dosage increases should not occur more rapidly than every 4 weeks, so that the physician can assess the patient's response to each dosage level. If the patient does not respond adequately, and no additional benefit is observed with-higher doses, the lowest dose that achieved maximal response should be used and other therapeutic approaches considered.